Tumor Biology

, Volume 36, Issue 5, pp 3251–3261 | Cite as

RETRACTED ARTICLE: Evidence for involvement of steroid receptors and coactivators in neuroepithelial and meningothelial tumors

  • Mengying Liu
  • Kaiyuan Zhang
  • Yangang Zhao
  • Qiang Guo
  • Deyu Guo
  • Jiqiang Zhang
Research Article


Steroid receptors such as androgen receptor (AR) and estrogen receptors (ER) ER-α and ER-β, and their receptor coactivators (steroid receptor coactivator, SRC) are widely localized in the brain. Although previous studies have investigated the expression of steroid receptors in brain tumors like astrocytoma, the studies on the expression of steroid receptors and SRCs in other brain tumors are lacking. Here, we investigated the expression of AR, ERs, and SRCs in neuroepithelial (medulloblastoma, ependymoma, oligodendroglioma) and meningothelial meningioma using tissue microarray immunohistochemistry. Compared to normal brain tissue, we found that the expression of SRC-1, SRC-3, and ER-α significantly decreased in meningothelial tumor and neuroepithelial tumor, suggesting that the SRC-1/SRC-3 levels may be regulated by ER-α. Moreover, the levels of AR strongly correlated to the levels of ER-β. Furthermore, correlation was also detected between SRC-3 and AR in neuroepithelial tumor, and between ER-α and ER-β in meningothelial tumor. In addition, the decreased ratio of SRC-1/SRC-3 was associated with an increase of ER-β in neuroepithelial tumor. These results indicate that expressions of different steroid receptors and activators may be tumor type dependent. While AR, ER-α, and ER-β may be involved in the pathogenesis of meningothelial tumor, SRCs/ER-β axis and SRC-3/AR axis may play a role in the pathogenesis of neuroepithelial tumor.


Brain tumor Meningioma Medulloblastoma Ependymoma Oligodendroglioma Steroid receptor Steroid receptor coactivator 



This study was supported by a grant from the National Natural Science Foundation of China (No. 81171526).

Conflicts of interest



  1. 1.
    Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimer’s disease. Horm Behav. 2013;63(2):301–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Baudry M, Bi X, Aguirre C. Progesterone-estrogen interactions in synaptic plasticity and neuroprotection. Neuroscience. 2013;239:280–94.CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang JQ, Cai WQ, Zhou DS, Su BY. Distribution and differences of estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain Res. 2002;935(1–2):73–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Fernandez-Guasti A, Kruijver FP, Fodor M, Swaab DF. Sex differences in the distribution of androgen receptors in the human hypothalamus. J Comp Neurol. 2000;425(3):422–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Kruijver FP, Fernandez-Guasti A, Fodor M, Kraan EM, Swaab DF. Sex differences in androgen receptors of the human mamillary bodies are related to endocrine status rather than to sexual orientation or transsexuality. J Clin Endocrinol Metab. 2001;86(2):818–27.CrossRefPubMedGoogle Scholar
  6. 6.
    Liu F, Day M, Muniz LC, Bitran D, Arias R, Revilla-Sanchez R, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci. 2008;11(3):334–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Bean LA, Ianov L, Foster TC. Estrogen receptors, the hippocampus, and memory. Neuroscientist. 2014.Google Scholar
  8. 8.
    Clipperton-Allen AE, Lee AW, Reyes A, Devidze N, Phan A, Pfaff DW, et al. Oxytocin, vasopressin and estrogen receptor gene expression in relation to social recognition in female mice. Physiol Behav. 2012;105(4):915–24.CrossRefPubMedGoogle Scholar
  9. 9.
    Jones BA, Watson NV. Spatial memory performance in androgen insensitive male rats. Physiol Behav. 2005;85(2):135–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Cowppli-Bony A, Bouvier G, Rue M, Loiseau H, Vital A, Lebailly P, et al. Brain tumors and hormonal factors: review of the epidemiological literature. Cancer Causes Control. 2011;22(5):697–714.CrossRefPubMedGoogle Scholar
  11. 11.
    Chung YG, Kim HK, Lee HK, Lee KC. Expression of androgen receptors in astrocytoma. J Korean Med Sci. 1996;11(6):517–21.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Carroll RS, Zhang J, Dashner K, Sar M, Black PM. Steroid hormone receptors in astrocytic neoplasms. Neurosurgery. 1995;37(3):496–503. discussion 503–494.CrossRefPubMedGoogle Scholar
  13. 13.
    Kefalopoulou Z, Tzelepi V, Zolota V, Grivas PD, Christopoulos C, Kalofonos H, et al. Prognostic value of novel biomarkers in astrocytic brain tumors: nuclear receptor co-regulators AIB1, TIF2, and PELP1 are associated with high tumor grade and worse patient prognosis. J Neurooncol. 2012;106(1):23–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Schnegg JF, Gomez F, LeMarchand-Beraud T, de Tribolet N. Presence of sex steroid hormone receptors in meningioma tissue. Surg Neurol. 1981;15(6):415–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Tilzer LL, Plapp FV, Evans JP, Stone D, Alward K. Steroid receptor proteins in human meningiomas. Cancer. 1982;49(4):633–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Lee LS, Chi CW, Chang TJ, Chou MD, Liu HC, Liu TY. Steroid hormone receptors in meningiomas of Chinese patients. Neurosurgery. 1989;25(4):541–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Leaes CG, Meurer RT, Coutinho LB, Ferreira NP, Pereira-Lima JF, da Costa Oliveira M. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology. 2010;30(1):44–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Takei H, Buckleair LW, Powell SZ. Immunohistochemical expression of apoptosis regulating proteins and sex hormone receptors in meningiomas. Neuropathology. 2008;28(1):62–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Fakhrjou A, Meshkini A, Shadrvan S. Status of Ki-67, estrogen and progesterone receptors in various subtypes of intracranial meningiomas. Pak J Biol Sci. 2012;15(11):530–5.CrossRefPubMedGoogle Scholar
  20. 20.
    Mancuso M, Leonardi S, Ceccarelli M, Pasquali E, De Stefano I, Prisco MG, et al. Protective role of 17 beta-estradiol on medulloblastoma development in Patched 1 heterozygous mice. Int J Cancer. 2010;127(12):2749–57.CrossRefPubMedGoogle Scholar
  21. 21.
    Mancuso M, Leonardi S, Giardullo P, Pasquali E, Borra F, Stefano ID, et al. The estrogen receptor beta agonist diarylpropionitrile (DPN) inhibits medulloblastoma development via anti-proliferative and pro-apototic pathways. Cancer Lett. 2011;308(2):197–202.CrossRefPubMedGoogle Scholar
  22. 22.
    Belcher SM, Ma X, Le HH. Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology. 2009;150(3):1112–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH, et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011;333(6048):1453–5.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Batistatou A, Kyzas PA, Goussia A, Arkoumani E, Voulgaris S, Polyzoidis K, et al. Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol. 2006;77(1):17–23.CrossRefPubMedGoogle Scholar
  25. 25.
    Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, Agnantis NJ. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol. 2004;130(7):405–10.CrossRefPubMedGoogle Scholar
  26. 26.
    Onate SA, Tsai SY, Tsai MJ, O’Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 1995;270(5240):1354–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A. 1996;93(10):4948–52.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Li H, Gomes PJ, Chen JD. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A. 1997;94(16):8479–84.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277(5328):965–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Nishihara E, Yoshida-Komiya H, Chan CS, Liao L, Davis RL, O’Malley BW, et al. SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. J Neurosci. 2003;23(1):213–22.PubMedGoogle Scholar
  31. 31.
    Ogawa H, Nishi M, Kawata M. Localization of nuclear coactivators p300 and steroid receptor coactivator 1 in the rat hippocampus. Brain Res. 2001;890(2):197–202.CrossRefPubMedGoogle Scholar
  32. 32.
    Bian C, Zhu K, Guo Q, Xiong Y, Cai W, Zhang J. Sex differences and synchronous development of steroid receptor coactivator-1 and synaptic proteins in the hippocampus of postnatal female and male C57BL/6 mice. Steroids. 2012;77(1–2):149–56.CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang D, Guo Q, Bian C, Zhang J, Lin S, Su B. Alterations of steroid receptor coactivator-1 (SRC-1) immunoreactivities in specific brain regions of young and middle-aged female Sprague–Dawley rats. Brain Res. 2011;1382:88–97.CrossRefPubMedGoogle Scholar
  34. 34.
    Bian C, Zhang D, Guo Q, Cai W, Zhang J. Localization and sex-difference of steroid receptor coactivator-1 immunoreactivities in the brain of adult female and male mice. Steroids. 2011;76(3):269–79.CrossRefPubMedGoogle Scholar
  35. 35.
    Liu C, Zhang Y, Zhang K, Bian C, Zhao Y, Zhang J. Expression of estrogen receptors, androgen receptor and steroid receptor coactivator-3 is negatively correlated to the differentiation of astrocytic tumours. Cancer Epidemiol. 2014. doi: 10.1016/ j.canep.2014.1003.1001.Google Scholar
  36. 36.
    Wang H, Zhang D, Wu W, Zhang J, Guo D, Wang Q, et al. Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem. 2010;58(12):1121–7.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Walsh CA, Qin L, Tien JC, Young LS, Xu J. The function of steroid receptor coactivator-1 in normal tissues and cancer. Int J Biol Sci. 2012;8(4):470–85.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Hernandez-Hernandez OT, Rodriguez-Dorantes M, Gonzalez-Arenas A, Camacho-Arroyo I. Progesterone and estradiol effects on SRC-1 and SRC-3 expression in human astrocytoma cell lines. Endocrine. 2010;37(1):194–200.CrossRefPubMedGoogle Scholar
  39. 39.
    Gonzalez-Arenas A, Hansberg-Pastor V, Hernandez-Hernandez OT, Gonzalez-Garcia TK, Henderson-Villalpando J, Lemus-Hernandez D, et al. Estradiol increases cell growth in human astrocytoma cell lines through ERalpha activation and its interaction with SRC-1 and SRC-3 coactivators. Biochim Biophys Acta. 2012;1823(2):379–86.CrossRefPubMedGoogle Scholar
  40. 40.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Liu C, Zhang Y, Zhang K, Bian C, Zhao Y, Zhang J. Expression of estrogen receptors, androgen receptor and steroid receptor coactivator-3 is negatively correlated to the differentiation of astrocytic tumors. Cancer Epidemiol. 2014;38(3):291–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Bao X, Cao L, Piao H, Xie L. Treatment-related secondary cancer in malignant meningiomas: a population-based study. J Cancer Res Clin Oncol. 2014;140(4):583–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Fujimoto M, Yoshino E, Hirakawa K, Fujimoto J, Tamaya T. Estrogen receptors in brain tumors. Clin Neuropharmacol. 1984;7(4):357–62.CrossRefPubMedGoogle Scholar
  44. 44.
    Tao Y, Liang G, Li Z, Wang Y, Wu A, Wang H, et al. Clinical features and immunohistochemical expression levels of androgen, estrogen, progesterone and Ki-67 receptors in relationship with gross-total resected meningiomas relapse. Br J Neurosurg. 2012;26(5):700–4.CrossRefPubMedGoogle Scholar
  45. 45.
    Baxter DS, Orrego A, Rosenfeld JV, Mathiesen T. An audit of immunohistochemical marker patterns in meningioma. J Clin Neurosci. 2014;21(3):421–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Pencovich N, Bot G, Lidar Z, Korn A, Wostrack M, Meyer B, Bydon M, Jallo G, Constantini S. Spinal ependymoma with regional metastasis at presentation. Acta Neurochir (Wien). 2014;Mar 8. [Epub ahead of print].Google Scholar
  47. 47.
    Deval B, Rousset P, Bigenwald C, Nogales FF, Alexandre J. Treatment of ovarian anaplastic ependymoma by an aromatase inhibitor. Obstet Gynecol. 2014;123(2 Pt 2 Suppl 2):488–91.CrossRefPubMedGoogle Scholar
  48. 48.
    Stolnicu S, Furtado A, Sanches A, Nicolae A, Preda O, Hincu M, et al. Ovarian ependymomas of extra-axial type or central immunophenotypes. Hum Pathol. 2011;42(3):403–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Matsuyama A, Hisaoka M, Yamamoto I, Toyoshima S, Hashimoto H. Extraspinal ependymoma of the broad ligament. Pathol Int. 2010;60(3):241–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Concolino G, Liccardo G, Conti C, Panfili C, Giuffre R. Hormones and tumours in central nervous system (CNS): steroid receptors in primary spinal cord tumours. Neurol Res. 1984;6(3):121–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Favaro R, Appolloni I, Pellegatta S, Sanga AB, Pagella P, Gambini E, Pisati F, Ottolenghi S, Foti M, Finocchiaro G, Malatesta P, Nicolis SK. Sox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res. 2014.Google Scholar
  52. 52.
    Dong SM, Pang JC, Poon WS, Hu J, To KF, Chang AR, et al. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors. J Neuropathol Exp Neurol. 2001;60(8):808–16.CrossRefPubMedGoogle Scholar
  53. 53.
    Ramachandran C, Khatib Z, Petkarou A, Fort J, Fonseca HB, Melnick SJ, et al. Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells. J Neurooncol. 2004;67(1–2):19–28.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Neurobiology, Chongqing Key Laboratory of NeurobiologyThird Military Medical UniversityChongqingChina
  2. 2.Cadet BrigadeThird Military Medical UniversityChongqingChina
  3. 3.Institute of Pathology, Southwest HospitalThird Military Medical UniversityChongqingChina

Personalised recommendations